Commentary only goes so far. Alongside the briefings, we build open tools that turn evidence into something teams can actually use — to quantify the economic burden of cancer, to see where access falls short, to right-size treatment, and to plan for what's coming. A selection is shown below; more are in development.
The full economic picture of cancer, tumour stream by tumour stream — direct medical costs alongside the wider societal burden of informal care and lost productivity. Compare across major cancers and across countries and income groups worldwide, drawing on our peer-reviewed cost-of-illness research.
Look ahead: project the future economic burden of cancer — direct and indirect costs — under different demographic, incidence and intervention scenarios. Built to inform long-term health-policy and capacity planning at national and global scale.
An interactive map of disparities in access to cancer diagnostics and therapies — across regions, income levels and populations. Spot where the gap between what exists and what reaches patients is widest, and track it over time.
A living, curated library of where doing less is proven safe — shorter regimens, omitted steps, active surveillance. Filter by tumour type and strength of evidence to support right-sized care without sacrificing outcomes.
Track emerging cancer technologies — diagnostics, therapies, devices — from trial to approval, with a plain-language read on likely system impact, cost and readiness requirements. Know what's coming before it arrives.
A structured self-assessment that helps a service gauge whether it's ready to adopt a given innovation — workforce, financing, pathways, monitoring — and pinpoints the gaps to close first.
Weigh the outcomes a therapy delivers against what it costs a system to provide it — including biosimilar and generic scenarios — to inform procurement and reimbursement conversations.
Compare local pathways against current international guidelines to surface where practice diverges — a first step toward reducing both under- and over-treatment.
We collaborate on open tools for cancer care and innovation. If you're developing one — or need one — we'd like to hear from you.
Get in touch